The MOHW Releases Two Major Benefits to Support Biomedical

The Deputy Minister of the Ministry of Health and Welfare, Mr. Chung-Liang Shih, announced on October 6, 2020, that in order to expedite the legislative process the “Act for the Development of Regenerative Medicine” will be removed from the proposal. This leaves the “Regulation Governing Regenerative Medicine” and the “Regulation Governing Regenerative Medicinal Products” to be reviewed and examined in this session of 2022. The reason for removal, according to. Mr. Shih, is that the current “Act for the Development of Biotech and Pharmaceutical Industry” already has similar tax preferences and rewards to incentivize the business. On the contrary, the regulations can effectively promote the massive production of cell therapy products and reduce the production price in a manner that will benefit society as a whole.
In the meantime, though the limitations set forth in Article 35(1) of the Medical Act stipulate that juridical persons in medical care cannot invest in a company more than 20% of the capital value of the invested company, the limitations will be relaxed. If one of the following conditions is met, juridical persons in medical care will not be subject to the aforesaid limitation:
Previous Back to list Next